A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor

Summary

This study is an open-label, dose-escalation, multicenter Phase I/II study conducted in patients with advanced solid tumors. The target population for this study consists of patients with advanced solid tumors who have failed or are intolerant to standard treatments. The study is divided into two parts: the dose-escalation phase and the dose-expansion phase.

Timeline

Start

2026-01-31

Primary completion

2027-12-31

Completion

2028-06-30

Drugs

Indications